Effect of miglitol as an add-on to bolus insulin on postprandial glycemic excursions in type 2 diabetes patients assessed by continuous glucose monitoring

Diabetes Technology and Therapeutics

Volumn 14, Issue 5, 2012, Pages 423-429

  Matsuura, Kenichi ^a   Mori, Yutaka ^a,b   Nakamura, Asuka ^a   Yokoyama, Junichi ^a   Utsunomiya, Kazunori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Kawachi gun   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; MIGLITOL; SHORT ACTING INSULIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN INFUSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ASSESSMENT; POSTPRANDIAL STATE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; TREATMENT DURATION;

1-DEOXYNOJIRIMYCIN; ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860591198     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0188     Document Type: Article

References (9)

1. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617-621.
2. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999;22:920-924.
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853.
4. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572.
5. IDF Clinical Guidelines Task Force: Guideline for Management of Postmeal Glucose. Brussels: International Diabetes Federation, 2011.
6. Hermanns N, Burkert A, Haak T: The addition of acarbose to insulin lispro reduces acute glycaemic responses in patients with type-2 diabetes. Exp Clin Endocrinol Diabetes 2004; 112:310-314.
7. Kubo S, Watada H, Kawamori R: Combination therapy of miglitol and insulin in type 1 diabetes mellitus patients. J Diabetes Investigation 2010;1:60-65.
8. Nemoto M, Tajima N, Kawamori R: Efficacy of combined use of miglitol in Type 2 diabetes patients receiving insulin therapy-placebo-controlled double-blind comparative study. Acta Diabetol 2011;48:15-20.
9. Tsujino D, Nishimura R, Taki K, Morimoto A, Tajima N, Utsunomiya K: Comparing the efficacy of a-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study. Diabetes Technol Ther 2011;13:303-308.